Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial.

Lancet Reg Health Southeast Asia · 2026 · PMC12969808 · PMID 41810147

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

21 , 40 In our study, EFS analysis stratified by pathological response showed a numerical trend toward better outcomes in MPR patients (median EFS 18·5 months) versus non-MPR (16·1 months), though the difference was not statistically significant, likely due to the modest sample size and short follow-up.

also in 691 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.